- NewBiologix has licensed its Xcell-Eng-HEK293 cell line to Recipharm Advanced Bio to improve adeno-associated virus (AAV) production.
- Recipharm has reported AAV yields exceeding 2E15 vg/L and >95% full capsids using the licensed technology.
NewBiologix, a biotechnology firm focused on viral vector production for cell and gene therapy (C>), has granted a non-exclusive licence to Recipharm Advanced Bio, the advanced therapies division of Recipharm and a global CDMO, for its Xcell-Eng-HEK293 cell line.
The licensed technology supports the manufacture of recombinant adeno-associated viruses (rAAV) and aims to accelerate development timelines for C> programmes. NewBiologix’s cell lines are cGMP-ready and designed to deliver high-yield, stable viral particle production across multiple serotypes.
According to the press release, Recipharm Advanced Bio has applied this cell line technology to achieve vector genome titres consistently exceeding 2E15 vg/L, including with gene constructs up to 5kb in size. The company also reports over 95% full capsids in final formulations, which contributes to process efficiency and downstream scalability.
The collaboration enables Recipharm to integrate the Xcell-Eng-HEK293 cell line into its end-to-end AAV manufacturing platform, from RUO to GMP. The technology has demonstrated applicability across more than 10 AAV serotypes.
“Our technology licensing agreement for ReciBioPharm, a global leader in ATMP development and manufacturing, will help ensure patients benefit from life-saving treatments through economically viable, large-scale production of viral vectors,” said Igor Fisch, CEO and co-founder of NewBiologix.
